Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Deferoxamine Mesylate
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved
Sponsor : Mitem Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
MITEM Pharma Acquires DESFERAL® Rights Backed by TECHLIFE CAPITAL, MACSF
Details : Mitem acquires Desfera (deferoxamine mesylate) products from Novartis. It is indicated for treating iron overload, and forex, following blood transfusions necessary for treating beta-thalassemia.
Brand Name : Desfera
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 25, 2024
Lead Product(s) : Deferoxamine Mesylate
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved
Sponsor : Mitem Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Deferoxamine Mesylate
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The trial will investigate the company’s Deferoxamine Intradermal Drug Patch (DIDP), for the topical treatment of Sickle Cell Leg Ulcers (SCUs) in support of its Orphan Drug Designation awarded in March of 2019.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 15, 2020
Lead Product(s) : Deferoxamine Mesylate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?